Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative…

COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501

Reconciliation of our segment profit
to consolidated income (loss) before income taxes
 Three months ended
 September 30,
  2026 2025
 (U.S.$ in millions)
      
United States profit$791 $927
Europe profit 420  303
International Markets profit 125  95
Total reportable segment profit 1,336  1,325
Profit (loss) of other activities 57  (31)
Amounts not allocated to segments:     
Amortization 139  144
Other asset impairments, restructuring and other items 264  62
Intangible asset impairments 24  64
Legal settlements and loss contingencies 201  60
Other unallocated amounts 51  82
Consolidated operating income (loss) 714  882
Financial expenses – net 414  237
Consolidated income (loss) before income taxes$300 $646
Scroll to Top